Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Nancy Kohl
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Genes & Molecular Sequences
Concepts & Ideas
Physiology
Occupations
Anatomy
Sign-in to see full Profile
Network (preview)
31
Gibbs, Jackson
26
Hartman, George
26
Oliff, Allen
24
Lobell, Robert
23
Graham, Samuel
20
Koblan, Kenneth
17
Buser, Carolyn
16
Omer, CA
15
Rands, Elaine
15
Davide, Joseph
14
deSolms, Jane
14
Williams, Theresa
13
Walsh, Eileen
13
Mosser, Scott
11
Schaber, Michael
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Nancy Kohl (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Rao Sudhir S; O'Neil Jennifer; Liberator Cole D; Hardwick James S; Dai Xudong; Zhang Theresa; Tyminski Edyta; Yuan Jing; Kohl Nancy E; Richon Victoria M; Van der Ploeg Lex H T; Carroll Pamela M; Draetta Giulio F; Look A Thomas; Strack Peter R; Winter Christopher G
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Cancer research 2009;69(7):3060-8.
-
2008: Cox Christopher D; Coleman Paul J; Breslin Michael J; Whitman David B; Garbaccio Robert M; Fraley Mark E; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Schaber Michael D; Lobell Robert B; Tao Weikang; Davide Joseph P; Diehl Ronald E; Abrams Marc T; South Vicki J; Huber Hans E; Torrent Maricel; Prueksaritanont Thomayant; Li Chunze; Slaughter Donald E; Mahan Elizabeth; Fernandez-Metzler Carmen; Yan Youwei; Kuo Lawrence C; Kohl Nancy E; Hartman George D
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Journal of medicinal chemistry 2008;51(14):4239-52.
-
2008: Wu Zhicai; Robinson Ronald G; Fu Sheng; Barnett Stanley F; Defeo-Jones Deborah; Jones Raymond E; Kral Astrid M; Huber Hans E; Kohl Nancy E; Hartman George D; Bilodeau Mark T
Rapid assembly of diverse and potent allosteric Akt inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(6):2211-4.
-
2007: Garbaccio Robert M; Tasber Edward S; Neilson Lou Anne; Coleman Paul J; Fraley Mark E; Olson Christy; Bergman Jeff; Torrent Maricel; Buser Carolyn A; Rickert Keith; Walsh Eileen S; Hamilton Kelly; Lobell Robert B; Tao Weikang; South Vicki J; Diehl Ronald E; Davide Joseph P; Yan Youwei; Kuo Lawrence C; Li Chunze; Prueksaritanont Thomayant; Fernandez-Metzler Carmen; Mahan Elizabeth A; Slaughter Donald E; Salata Joseph J; Kohl Nancy E; Huber Hans E; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2007;17(20):5671-6.
-
2007: Roecker Anthony J; Coleman Paul J; Mercer Swati P; Schreier John D; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Lobell Robert B; Tao Weikang; Diehl Ronald E; South Vicki J; Davide Joseph P; Kohl Nancy E; Yan Youwei; Kuo Lawrence C; Li Chunze; Fernandez-Metzler Carmen; Mahan Elizabeth A; Prueksaritanont Thomayant; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2007;17(20):5677-82.
-
2007: Coleman Paul J; Schreier John D; Cox Christopher D; Fraley Mark E; Garbaccio Robert M; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Lobell Robert B; Rickert Keith; Tao Weikang; Diehl Ronald E; South Vicki J; Davide Joseph P; Kohl Nancy E; Yan Youwei; Kuo Lawrence; Prueksaritanont Thomayant; Li Chunze; Mahan Elizabeth A; Fernandez-Metzler Carmen; Salata Joseph J; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2007;17(19):5390-5.
-
2007: Cox Christopher D; Breslin Michael J; Whitman David B; Coleman Paul J; Garbaccio Robert M; Fraley Mark E; Zrada Matthew M; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Lobell Robert B; Tao Weikang; Abrams Marc T; South Vicki J; Huber Hans E; Kohl Nancy E; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Bioorganic & medicinal chemistry letters 2007;17(10):2697-702.
-
2007: Lutterbach Bart; Zeng Qinwen; Davis Lenora J; Hatch Harold; Hang Gaozhen; Kohl Nancy E; Gibbs Jackson B; Pan Bo-Sheng
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Cancer research 2007;67(5):2081-8.
-
2006: Cox Christopher D; Torrent Maricel; Breslin Michael J; Mariano Brenda J; Whitman David B; Coleman Paul J; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Schaber Michael D; Lobell Robert B; Tao Weikang; South Vicki J; Kohl Nancy E; Yan Youwei; Kuo Lawrence C; Prueksaritanont Thomayant; Slaughter Donald E; Li Chunze; Mahan Elizabeth; Lu Bing; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2006;16(12):3175-9.
-
2006: Fraley Mark E; Garbaccio Robert M; Arrington Kenneth L; Hoffman William F; Tasber Edward S; Coleman Paul J; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Fernandes Christine; Schaber Michael D; Lobell Robert B; Tao Weikang; South Victoria J; Yan Youwei; Kuo Lawrence C; Prueksaritanont Thomayant; Shu Cathy; Torrent Maricel; Heimbrook David C; Kohl Nancy E; Huber Hans E; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2006;16(7):1775-9.
-
2006: Garbaccio Robert M; Fraley Mark E; Tasber Edward S; Olson Christy M; Hoffman William F; Arrington Kenneth L; Torrent Maricel; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Schaber Michael D; Fernandes Christine; Lobell Robert B; Tao Weikang; South Vicki J; Yan Youwei; Kuo Lawrence C; Prueksaritanont Thomayant; Slaughter Donald E; Shu Cathy; Heimbrook David C; Kohl Nancy E; Huber Hans E; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Bioorganic & medicinal chemistry letters 2006;16(7):1780-3.
-
2006: Sisko John T; Tucker Thomas J; Bilodeau Mark T; Buser Carolyn A; Ciecko Patrice A; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Koester Timothy J; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McLoughlin Debra; Miller-Stein Cynthia M; Rodman Leonard D; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Thomas Kenneth A; Wong Bradley K; Hartman George D
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Bioorganic & medicinal chemistry letters 2006;16(5):1146-50.
-
2005: Tao Weikang; South Victoria J; Zhang Yun; Davide Joseph P; Farrell Linda; Kohl Nancy E; Sepp-Lorenzino Laura; Lobell Robert B
Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
Cancer cell 2005;8(1):49-59.
-
2005: Cox Christopher D; Breslin Michael J; Mariano Brenda J; Coleman Paul J; Buser Carolyn A; Walsh Eileen S; Hamilton Kelly; Huber Hans E; Kohl Nancy E; Torrent Maricel; Yan Youwei; Kuo Laurence C; Hartman George D
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Bioorganic & medicinal chemistry letters 2005;15(8):2041-5.
-
2005: Hardwick James S; Yang Yi; Zhang Chunsheng; Shi Bin; McFall Rosemary; Koury Elizabeth J; Hill Susan L; Dai Hongyue; Wasserman Robert; Phillips Robert L; Weinstein Edward J; Kohl Nancy E; Severino Michael E; Lamb John R; Sepp-Lorenzino Laura
Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling.
Molecular cancer therapeutics 2005;4(3):413-25.
-
2004: Bilodeau Mark T; Balitza Adrienne E; Koester Timothy J; Manley Peter J; Rodman Leonard D; Buser-Doepner Carolyn; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Heimbrook David C; Huckle William R; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McFall Rosemary C; McLoughlin Debra; Miller-Stein Cynthia M; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Subramanian Raju; Thomas Kenneth A; Wong Bradley K; Yu Sean; Hartman George D
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Journal of medicinal chemistry 2004;47(25):6363-72.
-
2004: Sepp-Lorenzino Laura; Rands Elaine; Mao Xianzhi; Connolly Brett; Shipman Jennifer; Antanavage Joanne; Hill Susan; Davis Lenora; Beck Stephen; Rickert Keith; Coll Kathleen; Ciecko Patrice; Fraley Mark; Hoffman William; Hartman George; Heimbrook David; Gibbs Jackson; Kohl Nancy; Thomas Kenneth
A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo.
Cancer research 2004;64(2):751-6.
-
2003: Lobell Robert B; Davide Joseph P; Kohl Nancy E; Burns H Donald; Eng Wai-Si; Gibson Raymond E
A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2003;8(4):430-8.
-
2003: deSolms S Jane; Ciccarone Terrence M; MacTough Suzanne C; Shaw Anthony W; Buser Carolyn A; Ellis-Hutchings Michelle; Fernandes Christine; Hamilton Kelly A; Huber Hans E; Kohl Nancy E; Lobell Robert B; Robinson Ronald G; Tsou Nancy N; Walsh Eileen S; Graham Samuel L; Beese Lorena S; Taylor Jeffrey S
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
Journal of medicinal chemistry 2003;46(14):2973-84.
-
2002: Lobell Robert B; Liu Dongming; Buser Carolyn A; Davide Joseph P; DePuy Elizabeth; Hamilton Kelly; Koblan Kenneth S; Lee Yih; Mosser Scott; Motzel Sherri L; Abbruzzese James L; Fuchs Charles S; Rowinsky Eric K; Rubin Eric H; Sharma Sunil; Deutsch Paul J; Mazina Kathryn E; Morrison Briggs W; Wildonger Lynne; Yao Siu-Long; Kohl Nancy E
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Molecular cancer therapeutics 2002;1(9):747-58.
-
2001: Lobell R B; Omer C A; Abrams M T; Bhimnathwala H G; Brucker M J; Buser C A; Davide J P; deSolms S J; Dinsmore C J; Ellis-Hutchings M S; Kral A M; Liu D; Lumma W C; Machotka S V; Rands E; Williams T M; Graham S L; Hartman G D; Oliff A I; Heimbrook D C; Kohl N E
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Cancer research 2001;61(24):8758-68.
-
2001: Bell I M; Gallicchio S N; Abrams M; Beshore D C; Buser C A; Culberson J C; Davide J; Ellis-Hutchings M; Fernandes C; Gibbs J B; Graham S L; Hartman G D; Heimbrook D C; Homnick C F; Huff J R; Kassahun K; Koblan K S; Kohl N E; Lobell R B; Lynch J J; Miller P A; Omer C A; Rodrigues A D; Walsh E S; Williams T M
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.
Journal of medicinal chemistry 2001;44(18):2933-49.
-
2001: Beshore D C; Bell I M; Dinsmore C J; Homnick C F; Culberson J C; Robinson R G; Fernandes C; Walsh E S; Abrams M T; Bhimnathwala H G; Davide J P; Ellis-Hutchings M S; Huber H A; Koblan K S; Buser C A; Kohl N E; Lobell R B; Chen I W; McLoughlin D A; Olah T V; Graham S L; Hartman G D; Williams T M
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 2001;11(14):1817-21.
-
2001: Bergman J M; Abrams M T; Davide J P; Greenberg I B; Robinson R G; Buser C A; Huber H E; Koblan K S; Kohl N E; Lobell R B; Graham S L; Hartman G D; Williams T M; Dinsmore C J
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorganic & medicinal chemistry letters 2001;11(11):1411-5.
-
2001: Mactough S C; Desolms S J; Shaw A W; Abrams M T; Ciccarone T M; Davide J P; Hamilton K A; Hutchinson J H; Koblan K S; Kohl N E; Lobell R B; Robinson R G; Graham S L
Diaryl ether inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 2001;11(10):1257-60.
-
2001: Trotter B W; Quigley A G; Lumma W C; Sisko J T; Walsh E S; Hamann C S; Robinson R G; Bhimnathwala H; Kolodin D G; Zheng W; Buser C A; Huber H E; Lobell R B; Kohl N E; Williams T M; Graham S L; Dinsmore C J
2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry letters 2001;11(7):865-9.
-
2001: Dinsmore C J; Bergman J M; Wei D D; Zartman C B; Davide J P; Greenberg I B; Liu D; O'Neill T J; Gibbs J B; Koblan K S; Kohl N E; Lobell R B; Chen I W; McLoughlin D A; Olah T V; Graham S L; Hartman G D; Williams T M
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
Bioorganic & medicinal chemistry letters 2001;11(4):537-40.
-
2000: Cohen-Jonathan E; Muschel R J; Gillies McKenna W; Evans S M; Cerniglia G; Mick R; Kusewitt D; Sebti S M; Hamilton A D; Oliff A; Kohl N; Gibbs J B; Bernhard E J
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
Radiation research 2000;154(2):125-32.
-
2000: Omer C A; Chen Z; Diehl R E; Conner M W; Chen H Y; Trumbauer M E; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams M T; Davide J P; Ellis M S; Gibbs J B; Greenberg I; Koblan K S; Kral A M; Liu D; Lobell R B; Miller P J; Mosser S D; O'Neill T J; Rands E; Schaber M D; Senderak E T; Oliff A; Kohl N E
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Cancer research 2000;60(10):2680-8.
-
2000: Sirotnak F M; Sepp-Lorenzino L; Kohl N E; Rosen N; Scher H I
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.
Cancer chemotherapy and pharmacology 2000;46(1):79-83.
-
1999: Dinsmore C J; Williams T M; O'Neill T J; Liu D; Rands E; Culberson J C; Lobell R B; Koblan K S; Kohl N E; Gibbs J B; Oliff A I; Graham S L; Hartman G D
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 1999;9(23):3301-6.
-
1999: Mahgoub N; Taylor B R; Gratiot M; Kohl N E; Gibbs J B; Jacks T; Shannon K M
In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
Blood 1999;94(7):2469-76.
-
1999: Williams T M; Bergman J M; Brashear K; Breslin M J; Dinsmore C J; Hutchinson J H; MacTough S C; Stump C A; Wei D D; Zartman C B; Bogusky M J; Culberson J C; Buser-Doepner C; Davide J; Greenberg I B; Hamilton K A; Koblan K S; Kohl N E; Liu D; Lobell R B; Mosser S D; O'Neill T J; Rands E; Schaber M D; Huff J R
N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.
Journal of medicinal chemistry 1999;42(19):3779-84.
-
1999: Anthony N J; Gomez R P; Schaber M D; Mosser S D; Hamilton K A; O'Neil T J; Koblan K S; Graham S L; Hartman G D; Shah D; Rands E; Kohl N E; Gibbs J B; Oliff A I
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Journal of medicinal chemistry 1999;42(17):3356-68.
-
1999: Ciccarone T M; MacTough S C; Williams T M; Dinsmore C J; O'Neill T J; Shah D; Culberson J C; Koblan K S; Kohl N E; Gibbs J B; Oliff A I; Graham S L; Hartman G D
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 1999;9(14):1991-6.
-
1999: Nørgaard P; Law B; Joseph H; Page D L; Shyr Y; Mays D; Pietenpol J A; Kohl N E; Oliff A; Coffey R J; Poulsen H S; Moses H L
Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):35-42.
-
1999: Kohl N E
Farnesyltransferase inhibitors. Preclinical development.
Annals of the New York Academy of Sciences 1999;886():91-102.
-
1998: Lingham R B; Silverman K C; Jayasuriya H; Kim B M; Amo S E; Wilson F R; Rew D J; Schaber M D; Bergstrom J D; Koblan K S; Graham S L; Kohl N E; Gibbs J B; Singh S B
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Journal of medicinal chemistry 1998;41(23):4492-501.
-
1998: deSolms S J; Giuliani E A; Graham S L; Koblan K S; Kohl N E; Mosser S D; Oliff A I; Pompliano D L; Rands E; Scholz T H; Wiscount C M; Gibbs J B; Smith R L
N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
Journal of medicinal chemistry 1998;41(14):2651-6.
-
1998: Lobell R B; Kohl N E
Pre-clinical development of farnesyltransferase inhibitors.
Cancer metastasis reviews 1998;17(2):203-10.
-
1998: Mangues R; Corral T; Kohl N E; Symmans W F; Lu S; Malumbres M; Gibbs J B; Oliff A; Pellicer A
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Cancer research 1998;58(6):1253-9.
-
1998: Moasser M M; Sepp-Lorenzino L; Kohl N E; Oliff A; Balog A; Su D S; Danishefsky S J; Rosen N
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1369-74.
-
1998: Barrington R E; Subler M A; Rands E; Omer C A; Miller P J; Hundley J E; Koester S K; Troyer D A; Bearss D J; Conner M W; Gibbs J B; Hamilton K; Koblan K S; Mosser S D; O'Neill T J; Schaber M D; Senderak E T; Windle J J; Oliff A; Kohl N E
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Molecular and cellular biology 1998;18(1):85-92.
-
1998: Kohl N E; Koblan K S; Omer C A; Oliff A; Gibbs J B
Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
Methods in molecular biology (Clifton, N.J.) 1998;84():283-91.
-
1997: Omer C A; Kohl N E
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.
Trends in pharmacological sciences 1997;18(11):437-44.
-
1997: Kral A M; Diehl R E; deSolms S J; Williams T M; Kohl N E; Omer C A
Mutational analysis of conserved residues of the beta-subunit of human farnesyl:protein transferase.
The Journal of biological chemistry 1997;272(43):27319-23.
-
1997: Gibbs J B; Graham S L; Hartman G D; Koblan K S; Kohl N E; Omer C A; Oliff A
Farnesyltransferase inhibitors versus Ras inhibitors.
Current opinion in chemical biology 1997;1(2):197-203.
-
1997: Omer C A; Anthony N J; Buser-Doepner C A; Burkhardt A L; deSolms S J; Dinsmore C J; Gibbs J B; Hartman G D; Koblan K S; Lobell R B; Oliff A; Williams T M; Kohl N E
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
BioFactors (Oxford, England) 1997;6(3):359-66.
-
1996: Koblan K S; Kohl N E; Omer C A; Anthony N J; Conner M W; deSolms S J; Williams T M; Graham S L; Hartman G D; Oliff A; Gibbs J B
Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Biochemical Society transactions 1996;24(3):688-92.
-
1996: Prendergast G C; Davide J P; Lebowitz P F; Wechsler-Reya R; Kohl N E
Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
Cancer research 1996;56(11):2626-32.
-
1996: Williams T M; Ciccarone T M; MacTough S C; Bock R L; Conner M W; Davide J P; Hamilton K; Koblan K S; Kohl N E; Kral A M; Mosser S D; Omer C A; Pompliano D L; Rands E; Schaber M D; Shah D; Wilson F R; Gibbs J B; Graham S L; Hartman G D; Oliff A I; Smith R L
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Journal of medicinal chemistry 1996;39(7):1345-8.
-
1996: Gibbs J B; Kohl N E; Koblan K S; Omer C A; Sepp-Lorenzino L; Rosen N; Anthony N J; Conner M W; deSolms S J; Williams T M; Graham S L; Hartman G D; Oliff A
Farnesyltransferase inhibitors and anti-Ras therapy.
Breast cancer research and treatment 1996;38(1):75-83.
-
1995: Sepp-Lorenzino L; Ma Z; Rands E; Kohl N E; Gibbs J B; Oliff A; Rosen N
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Cancer research 1995;55(22):5302-9.
-
1995: deSolms S J; Deana A A; Giuliani E A; Graham S L; Kohl N E; Mosser S D; Oliff A I; Pompliano D L; Rands E; Scholz T H
Pseudodipeptide inhibitors of protein farnesyltransferase.
Journal of medicinal chemistry 1995;38(20):3967-71.
-
1995: Kohl N E; Omer C A; Conner M W; Anthony N J; Davide J P; deSolms S J; Giuliani E A; Gomez R P; Graham S L; Hamilton K
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.
Nature medicine 1995;1(8):792-7.
-
1995: Kohl N E; Conner M W; Gibbs J B; Graham S L; Hartman G D; Oliff A
Development of inhibitors of protein farnesylation as potential chemotherapeutic agents.
Journal of cellular biochemistry. Supplement 1995;22():145-50.
-
1995: Kohl N E; Wilson F R; Thomas T J; Bock R L; Mosser S D; Oliff A; Gibbs J B
Inhibition of Ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase.
Methods in enzymology 1995;255():378-86.
-
1994: Kohl N E; Wilson F R; Mosser S D; Giuliani E; deSolms S J; Conner M W; Anthony N J; Holtz W J; Gomez R P; Lee T J
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(19):9141-5.
-
1994: Prendergast G C; Davide J P; deSolms S J; Giuliani E A; Graham S L; Gibbs J B; Oliff A; Kohl N E
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
Molecular and cellular biology 1994;14(6):4193-202.
-
1994: Gibbs J B; Oliff A; Kohl N E
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.
Cell 1994;77(2):175-8.
-
1994: Graham S L; deSolms S J; Giuliani E A; Kohl N E; Mosser S D; Oliff A I; Pompliano D L; Rands E; Breslin M J; Deana A A
Pseudopeptide inhibitors of Ras farnesyl-protein transferase.
Journal of medicinal chemistry 1994;37(6):725-32.
-
1994: Sardana V V; Schlabach A J; Graham P; Bush B L; Condra J H; Culberson J C; Gotlib L; Graham D J; Kohl N E; LaFemina R L
Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site.
Biochemistry 1994;33(8):2004-10.
-
1994: Zhang F L; Diehl R E; Kohl N E; Gibbs J B; Giros B; Casey P J; Omer C A
cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I.
The Journal of biological chemistry 1994;269(5):3175-80.
-
1993: Prendergast G C; Davide J P; Kral A; Diehl R; Gibbs J B; Omer C A; Kohl N E
Negative growth selection against rodent fibroblasts targeted for genetic inhibition of farnesyl transferase.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1993;4(9):707-13.
-
1993: Kohl N E; Mosser S D; deSolms S J; Giuliani E A; Pompliano D L; Graham S L; Smith R L; Scolnick E M; Oliff A; Gibbs J B
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Science (New York, N.Y.) 1993;260(5116):1934-7.
-
1993: Omer C A; Kral A M; Diehl R E; Prendergast G C; Powers S; Allen C M; Gibbs J B; Kohl N E
Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases.
Biochemistry 1993;32(19):5167-76.
-
1993: Gibbs J B; Pompliano D L; Mosser S D; Rands E; Lingham R B; Singh S B; Scolnick E M; Kohl N E; Oliff A
Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
The Journal of biological chemistry 1993;268(11):7617-20.
-
1992: Jia S; VanDusen W J; Diehl R E; Kohl N E; Dixon R A; Elliston K O; Stern A M; Friedman P A
cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase.
The Journal of biological chemistry 1992;267(20):14322-7.
-
1991: Kohl N E; Diehl R E; Schaber M D; Rands E; Soderman D D; He B; Moores S L; Pompliano D L; Ferro-Novick S; Powers S
Structural homology among mammalian and Saccharomyces cerevisiae isoprenyl-protein transferases.
The Journal of biological chemistry 1991;266(28):18884-8.
-
1991: Kohl N E; Diehl R E; Rands E; Davis L J; Hanobik M G; Wolanski B; Dixon R A
Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.
Journal of virology 1991;65(6):3007-14.
-
1991: Darke P L; Kohl N E; Hanobik M G; Leu C T; Vacca J P; Guare J P; Heimbach J C; Dixon R A
Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors.
Advances in experimental medicine and biology 1991;306():483-7.
-
1990: DiIanni C L; Davis L J; Holloway M K; Herber W K; Darke P L; Kohl N E; Dixon R A
Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease.
The Journal of biological chemistry 1990;265(28):17348-54.
-
1988: Kohl N E; Emini E A; Schleif W A; Davis L J; Heimbach J C; Dixon R A; Scolnick E M; Sigal I S
Active human immunodeficiency virus protease is required for viral infectivity.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(13):4686-90.
Sign-in to see more
